GH Research posted a Q2 net loss of USD 15.1 million, or USD 0.23 per share, versus a USD 9.3 million loss a year earlier.
R&D expenses climbed to USD 12.4 million from USD 9.0 million; G&A costs rose to USD 7.1 million from USD 5.7 million.
Cash, cash equivalents and marketable securities totaled USD 362.7 million at June 30, up from USD 280.7 million at Dec. 31, 2025.
FDA written responses in July confirmed CMC and device plans appear Phase 3 ready; Phase 1 trials GH001-HV-106 and GH001-HV-109 were completed.
U.S. Patent No. 12,685,721 was granted with expected expiry no earlier than 2043; European Patent No. 3 927 337 was maintained with expected expiry no earlier than 2040.
GHRS•
